PATHOLOGICAL UPTAKE WITH 18-FLUOROCHOLINE VERSUS 99mTc-MIBI IN THE LOCATION OF THE PARATHYROID GLANDS IN HYPERPARATHYROIDISM.
SYSTEMATIC REVIEW AND META-ANALYSIS
PARDAL-REFOYO ET AL.

Title

Pathological uptake with 18-Fluorocholine versus 99mTc-MIBI in the location of the parathyroid glands in hyperparathyroidism. Systematic review and meta-analysis

Authors

José Luis Pardal Refoyo¹
Pilar Tamayo Alonso²
Sofía Ferreira Cendón¹
Esther Martín Gómez²

University Hospital of Salamanca
Salamanca Biomedical Research Institute (IBSAL)
¹ Otolaryngology and Head and Neck Surgery
² Nuclear Medicine

Contact

JL Pardal-Refoyo
jlpardal@usal.es

University Hospital of Salamanca
Otolaryngology and Head and Neck Surgery
Paseo de San Vicente 182
37007 Salamanca
Spain

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Summary

Introduction: The location of the pathological parathyroid glands in hyperparathyroidism is usually carried out by means of 99mTc-sestamibi scintigraphy, which increases its precision by adding the ultrasound examination. The non-localization of the parathyroid glands increases the difficulties for surgical removal. To increase the detection of pathological glands, other radioactive tracers are used, such as methionine, fluorocholine or 18F-flurpiridaz.

Objective: To establish if PET / CT with 18-Fluorocholine in patients with hyperparathyroidism increases the number of uptakes compared to the 99mTc-sestamibi scan.

Method: Systematic review and meta-analysis. Two subgroups were analyzed. Subgroup 1: trials comparing both techniques as an initial exploration. Thirteen studies including 1131 examinations were selected (596 PET / CT with 18-Fluorocholine vs. 535 scintigraphy with 99mTc-sestamibi). Meta-analysis was performed following the random effects model and the odds ratio was calculated. Subgroup 2: studies that include 18-Fluorocholine as a rescue examination in patients with a previous negative study with a 99mTc-sestamibi scan. 17 articles including 412 examinations with 359 patients in which there was at least one uptake were selected. Meta-analysis of the prevalence of the number of patients in whom there was at least one uptake was performed using the random effects model.

Results: Subgroup 1: The number of patients in which at least one uptake occurs is significantly higher with the 18-Fluorocholine examinations (OR 4.264, 95% CI 2.400-7.577). The prevalence of uptake with 18-Fluorocholine is 0.91 [0.86, 0.95] and with sestamibi 0.68 [0.56, 0.80]. Subgroup 2: the prevalence of uptake among patients with previous negative MIBI studies was 0.90 [0.87, 0.94]. The probability of detection of both techniques in this group reaches 0.98. Publication bias in the meta-analyses is low.

Discussion: 18-Fluorocholine protocols provide higher precision, clearer images, with faster acquisition as well as being readily available for most PET / CT centers.

Conclusion: The PET / CT study with 18-Fluorocholine can be recommended as a study for the location of pathological parathyroid glands after studies with negative MIBI.

Keywords: Hyperparathyroidism; parathyroid; sestamibi scintigraphy; choline PET; fluorocholine

Introduction

The location of the pathological parathyroid glands in hyperparathyroidism is usually performed by SPECT/TC scan with 99mTc-sestamibi (MIBI) which increases their accuracy when associating ultrasound scanning. The non-location of the parathyroid glands increases difficulties for surgical removal. Other radioactive tracers such as methionine or fluorocholine are used to increase the detection of pathological glands [1–8].

The usefulness of PET/TC with 18-Fluorocholine (CH) was established after incidental findings of pathological parathyroid in males tracking for prostate cancer. In 2012 Mapelli et al., in 2013 Quak et al. and, in 2014 Hodolic et al. described cases of incidental uptake in parathyroids in explorations with F-18-fluorocholine in males with prostate cancer and proposed it as a study in case of negative MIBI [9–11]. Subsequent studies have confirmed this indication [12–14].

The accuracy of nuclear scans in the location of pathological parathyroid glands in hyperparathyroidism has been widely published and debated in the literature and the absence of localization poses a greater difficulty in surgical treatment so research is continued to establish a diagnostic strategy that offers the highest number of true positives and fewer false negatives.

The objective of this review is to know whether PET/TC with 18-Fluorocholine in patients with hyperparathyroidism increases the number of catches compared to the scan with 99mTc-MIBI by bibliographic review.

Method

The following research PICO question was asked: In patients with primary hyperparathyroidism [patient] the location of the pathological glands [intervention] by PET/TC with 18-Fluorocholine (CH) versus SPECT/TC with 99mTc-MIBI (MIBI) [comparison] does it offer more detections with suspected pathology? [outcome].

Systematic review in the PubMed (<https://pubmed.ncbi.nlm.nih.gov/>), WoS (<http://wos.fecyt.es/>), ClinicalTrials (<https://clinicaltrials.gov/>) and Cochrane (<https://www.cochranelibrary.com/>) databases with closure on December 17, 2019 following the guidelines of the PRISMA group [15] and Cochrane method [16] with the search descriptors and strategies summarized in Figure 1.

Inclusion criteria: studies including patients with hyperparathyroidism undergoing scan with 99mTc-Sesta-MIBI (MIBI) and 18F-choline PET/CT (CH) as first scan (subgroup 1) and patients with study 99mTc-Sesta-MIBI (MIBI) negative in the first scan to be performed second rescue scan with 18F-choline PET/CT (CH) in which there was at least a significant scan uptake (subgroup 2). Articles indicating the number of patients scanned and the number of patients in whom there was at least a positive uptake in the neck or mediastinum and those in which there was no uptake or this nor was conclusive evaluated with SUVmax measurement (maximum standardized absorption value).

Exclusion criteria: clinical cases, conferences, conferences with published data or parathyroid cancer series exclusively.

Each article obtained the total number of patients with scans performed and calculated the prevalence of patients in which there was at least one uptake (positive uptake) or there was no uptake, or this was doubtful (negative uptake).

Two subgroups were analyzed:

Subgroup 1: essays comparing both techniques (CH vs. MIBI) as an initial scan.

Meta-analysis of dicotomical models was performed following the random effects model, the *odds ratio* and the publication bias were calculated.

Subgroup 2: studies that include CH as a rescue scan in patients with prior negative study with MIBI scan.

Meta-analysis of the prevalence of the number of patients in which there was at least one uptake was performed using the random effects model and the publication bias was evaluated.

The statistical program JAMOMI 1.2.22 (The jamovi project 2020, <https://www.jamovi.org>) was used.

Study limitations

- Only patients where at least one scan uptake was detected.
- The number of uptakes per patient was not evaluated.
- Patients with primary hyperparathyroidism are included but in some cases the diagnosis is not clear.
- Correlation of catchments with surgical findings was not sought to assess the accuracy of the tests.
- It is assumed that the scan uptake increases the probability of surgical location.

Results

Subgroup 1:

13 studies including 1131 scans (596 PET/TC with 18-Fluorocholine vs. 535 SPECT/TC scan with 99mTc-sestamibi) [14,17–28] were selected. See Table 1.

The number of patients with at least one uptake is significantly higher with 18-Fluorocholine scans (OR 4,264, CI 95% 2,400-7,577). The prevalence of uptakes with 18-Fluorocholine is 0.91 [0.86, 0.95] and with MIBI of 0.68 [0.56, 0.80]. See Figures 2 and 3.

The publication bias is moderate (I²-55.35%). See Figure 4.

Subgroup 2:

17 articles including 412 scans were selected with at least 359 patients in which there was at least one uptake [17,21,23,29–41]. See Table 2.

The prevalence of uptakes among patients with prior negative MIBI studies was 0.90 [0.87, 0.94].

The probability of detection of both techniques in this group reaches 0.98. See Figures 5 and 6.

The publication bias in meta-analysis is low (I²-34.5%). See Figure 7.

Discussion

Currently, the definitive treatment of hyperparathyroidism is the surgical removal of the gland or pathological glands. Negative localization studies make surgical treatment difficult.

In both the selected articles in our meta-analysis and in previous meta-analysis, CH localization studies have shown greater ability to locate pathological glands [34,42–45] than MIBI or methionine [46–48] in both first exploration and rescue scan [31,49].

The probability of uptake with CH is above 0.9 on both first scans and scans performed after negative MIBI study (in these cases the combination of both techniques reaches a prevalence of uptake of 0.97). See Figure 8.

The CH localization study using PET/TC offers advantages such as higher number of uptakes (both the number of patients with at least one uptake and the higher number of multiple adenoma or hyperplasia captures [20], shorter imaging time [14] and exposure of patients with less radiation than the SPECT/CT hybrid image with Tc-99m-sestaMIBI [50].

As disadvantages is the difficulty in distinguishing catches in thyroid, nodes, thymus or muscle (false positives) [50] and logistical problems [14].

CH scan may be indicated both as an initial scan and in patients with prior negative MIBI study.

Conclusions

1. Ultrasound-associated SPECT/TC-MIBI scan is currently the scan of choice for the location of pathological parathyroid glands prior to surgery.
2. PET-Choline scan increases the number of patients with at least one uptake on both the first scan and on scans with initial negative MIBI studies.
3. Currently PET-Choline scan seems an option to locate pathological glands in patients with negative initial scan.

References

1. Hindí E, Zanotti-Fregonara P, Tabarin A, Rubello D, Morelec I, Wagner T, et al. The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. *J Nucl Med*. 2015 May 1;56(5):737–44.
2. Lussey-Lepoutre C, Trésallet C, Ghander C, Morelec I, Najah H, Kasereka-kisenge F, et al. Rôle de l'imagerie dans le bilan préopératoire des hyperparathyroïdies primaires. *Med Nucl*. 2018 Jan 1;42(1):49–58.
3. Prior JO. New scintigraphic methods for parathyroid imaging. *Ann Endocrinol (Paris)*. 2015 May 1;76(2):145–7.
4. Weber T, Luster M. C-11-Methionin-PET/CT zur Lokalisation von Nebenschilddrüsenadenomen. Vol. 85, *Chirurg*. Springer Verlag; 2014. p. 601–6.
5. Grassetto G, Alavi A, Rubello D. PET and Parathyroid. Vol. 2, *PET Clinics*. 2007. p. 385–93.
6. Kettle AG, O'Doherty MJ. Parathyroid Imaging: How Good Is It and How Should It Be Done? *Semin Nucl Med*. 2006 Jul;36(3):206–11.
7. Imperiale A, Taïeb D, Hindí E. 18 F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism. Vol. 45, *European Journal of Nuclear Medicine and Molecular Imaging*. Springer Berlin Heidelberg; 2018. p. 654–7.
8. García-Talavera San Miguel P, Gómez-Caminero López F, Villanueva Curto JG, Tamayo Alonso MP, Martín Gómez ME. Update of the role of Nuclear Medicine techniques in the pre-surgical localization of primary hyperparathyroidism. *Rev Esp Med Nucl Imagen Mol*. 2019 Mar 1;38(2):123–35.
9. Mapelli P, Busnardo E, Magnani P, Freschi M, Picchio M, Gianolli L, et al. Incidental finding of parathyroid adenoma with 11C-choline PET/CT. *Clin Nucl Med*. 2012 Jun;37(6):593–5.
10. Quak E, Lheureux S, Reznik Y, Bardet S, Aide N. F18-choline, a novel PET tracer for parathyroid adenoma? Vol. 98, *Journal of Clinical Endocrinology and Metabolism*. 2013. p. 3111–2.
11. Hodolic M, Huchet V, Balogova S, Michaud L, Kerrou K, Nataf V, et al. Incidental uptake of 18F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. *Radiol Oncol*. 2014 Sep 1;48(3):228–34.
12. Parvinian A, Martin-Macintosh EL, Goenka AH, Durski JM, Mullan BP, Kemp BJ, et al. 11C-choline PET/CT for detection and localization of parathyroid adenomas. *Am J Roentgenol*. 2018 Feb 1;210(2):418–22.
13. Kluijfhout WP, Vorselaars WCM, Vriens MR, Borel Rinkes IHM, Valk GD, De Keizer B. Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of 18F-fluorocholine PET-CT. *Eur J Radiol*. 2015 Sep 1;84(9):1745–51.
14. Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, et al. A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: Influence of. *Med (United States)*. 2015;94(41).
15. Shamseer L, Moher D, Clarke M, Ghera D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015 Jan 2;350:g7647.
16. Centro Cochrane Iberoamericano traductores. *Manual Cochrane de Revisiones Sistemáticas de Intervenciones*, versión 5.1.0 [actualizada en marzo de 2011]. Barcelona; 2012. 639 p.
17. Thanseer N, Bhadada SK, Sood A, Mittal BR, Behera A, Gorla AKR, et al. Comparative Effectiveness of Ultrasonography, 99mTc-Sestamibi, and 18F-Fluorocholine PET/CT in Detecting Parathyroid Adenomas in Patients With Primary Hyperparathyroidism. *Clin Nucl Med*. 2017;42(12):e491–7.
18. Michaud L, Burgess A, Huchet V, Lefèvre M, Tassart M, Ohnona J, et al. Is 18F-fluorocholine-positron emission tomography/ computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? *J Clin Endocrinol Metab*. 2014 Dec 1;99(12):4531–6.
19. Khafif A, Masalha M, Landsberg R, Domachevsky L, Bernstine H, Groshar D, et al. The

- role of F18-fluorocholine positron emission tomography/magnetic resonance imaging in localizing parathyroid adenomas. *Eur Arch Oto-Rhino-Laryngology*. 2019;276(5):1509–16.
20. Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J. 18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. *Eur J Nucl Med Mol Imaging*. 2014;41(11):2083–9.
21. Orevi M, Freedman N, Mishani E, Bocher M, Jacobson O, Krausz Y. Localization of parathyroid adenoma by 11C-Choline PET/CT preliminary results. *Clin Nucl Med*. 2014;39(12):1033–8.
22. Beheshti M, Hehenwarter L, Paymani Z, Rendl G, Imamovic L, Rettenbacher R, et al. 18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. *Eur J Nucl Med Mol Imaging*. 2018 Sep 1;45(10):1762–71.
23. Araz, C. Soydal, E. Ozkan, M. Kir, E. İbis, S. Gullu MF, Erdogan, R. Emral ONK. The Efficacy of 18F Choline PET/CT in comparison to Tc99m MIBI SPECT/CT in the Localisation of Hyperfunctioning Parathyroid Gland in primary Hyperparathyroidism. *Eur J Nucl Med Mol Imaging*. 2018;45(Suppl. 1):S89–90.
24. Araz M, Soydal Ç, Özkan E, Kır MK, İbiş E, Güllü S, et al. The efficacy of fluorine-18-choline PET/CT in comparison with 99mTc-MIBI SPECT/CT in the localization of a hyperfunctioning parathyroid gland in primary hyperparathyroidism. *Nucl Med Commun*. 2018;39(11):989–94.
25. Bossert I, Chytiris S, Hodolic M, Croce L, Mansi L, Chiovato L, et al. PET/CT with 18 F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism. *J Endocrinol Invest*. 2019 Apr 2;42(4):419–26.
26. Imamovic L. F18 Choline PET-CT: an accurate diagnostic tool for the detection of parathyroid adenoma? *Mol imaging Biol Conf world Mol imaging Congr 2016 United states Conf start 20160907 Conf end 20160910*. 2016;(2 Supplement).
27. Hocevar M, Lezaic L, Rep S, Zaletel K, Kocjan T, Sever MJ, et al. Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with 18F-Fluorocholine PET/CT. *Eur J Surg Oncol*. 2017 Jan 1;43(1):133–7.
28. Kluijfhout WP, Vorselaars WMCM, Van Den Berk SAM, Vriens MR, Borel Rinkes IHM, Valk GD, et al. Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: A multicenter study from the Netherlands. *Nucl Med Commun*. 2016 Nov 1;37(12):1246–52.
29. Liu Y, Dang Y, Huo L, Hu Y, Wang O, Liu H, et al. Preoperative localisation of adenomas in primary hyperparathyroidism: the value of 11 C-choline PET/CT in patients with negative or discordant ultrasonography and 99m Tc-Sesta-MIBI-SPECT/CT. *J Nucl Med*. 2019 Oct 10;jnumed.119.233213.
30. Christakis I, Khan S, Sadler GP, Gleeson F V., Bradley KM, Mihai R. 18Fluorocholine PET/CT scanning with arterial phase-enhanced CT is useful for persistent/ recurrent primary hyperparathyroidism: First UK case series results. In: *Annals of the Royal College of Surgeons of England*. Royal College of Surgeons of England; 2019. p. 501–7.
31. Boccalatte LA, Higuera F, Gómez NL, De La Torre AY, Mazzaro EL, Galich AM, et al. Usefulness of 18F-fluorocholine positron emission tomography-computed tomography in locating lesions in hyperparathyroidism: A systematic review. Vol. 145, *JAMA Otolaryngology - Head and Neck Surgery*. American Medical Association; 2019. p. 743–50.
32. Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Lebouleux S, et al. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. *Eur J Nucl Med Mol Imaging*. 2018 Sep 1;45(10):1772–80.
33. Huber GF, Hüllner M, Schmid C, Brunner A, Sah B, Vetter D, et al. Benefit of 18 F-fluorocholine PET imaging in parathyroid surgery. Vol. 28, *European Radiology*. Springer Verlag; 2018. p. 2700–7.
34. Treglia G, Sadeghi R, Schalin-Jäntti C, Caldarella C, Ceriani L, Giovanella L. Detection rate of 99mTc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: A meta-analysis. Vol.

38. Head and Neck. John Wiley and Sons Inc.; 2016. p. E2159–72.
35. Piccardo A, Trimboli P, Rutigliani M, Puntoni M, Foppiani L, Bacigalupo L, et al. Additional value of integrated 18 F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. *Eur J Nucl Med Mol Imaging*. 2019;46(3):766–75.
36. Zajickova, K; Zogala, D; Kubinyi J. Parathyroid Imaging by 18F-Fluorocholine PET/CT in Patients With Primary Hyperparathyroidism and Inconclusive Conventional Methods: Clinico-Pathological Correlations. *Physiol Res*. 2018 Nov 30;S551–7.
37. Kluijfhout WP, Pasternak JD, Gosnell JE, Shen WT, Duh QY, Vriens MR, et al. 18F fluorocholine PET/MR imaging in patients with primary hyperparathyroidism and inconclusive conventional imaging: A prospective pilot study. *Radiology*. 2017 Aug 1;284(2):460–7.
38. Quak E, Blanchard D, Houdu B, Le Roux Y, Ciappuccini R, Lireux B, et al. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. *Eur J Nucl Med Mol Imaging*. 2018 Apr 1;45(4):658–66.
39. M. I. Morales-Lozano, C. Perdomo¹, F. Grisanti¹, O. Ajuria J, Rosales, C. Silva JA. Primary hyperparathyroidism and negative conventional imaging: value of 11C-Methionine PET/CT and comparison with 11C-Choline PET/CT. *Eur J Nucl Med Mol Imaging*. 2018;45(Suppl. 1):S88–9.
40. G. Bera, C. Amadou, M. Ezziame, L. Chami, T. Delbot, A. Rouxel M, Leban, G. Herve, F. Menegaux, L. Leenhardt, A. Kas, C. Tresalet C, Ghander CL-L. 18F-fluorocholine PET/CT and parathyroid 4D Computed Tomography: First results of an alternative and efficient imaging tool in reoperative patients with primary hyperparathyroidism. *Eur J Nucl Med Mol Imaging*. 2018;45(Suppl. 1):S90.
41. Amadou C, Bera G, Ezziame M, Chami L, Delbot T, Rouxel A, et al. 18F-Fluorocholine PET/CT and Parathyroid 4D Computed Tomography for Primary Hyperparathyroidism: The Challenge of Reoperative Patients. *World J Surg*. 2019 May 15;43(5):1232–42.
42. Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, et al. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging*. 2019;46(3):751–65.
43. Kim SJ, Lee SW, Jeong SY, Pak K, Kim K. Diagnostic Performance of F-18 Fluorocholine PET/CT for Parathyroid Localization in Hyperparathyroidism: a Systematic Review and Meta-Analysis. *Horm Cancer*. 2018;9(6):440–7.
44. Treglia G, Trimboli P, Huellner M, Giovanella L. Imaging in primary hyperparathyroidism: Focus on the evidence-based diagnostic performance of different methods. Vol. 43, *Minerva Endocrinologica*. Edizioni Minerva Medica; 2018. p. 133–43.
45. Broos WAM, Wondergem M, Knol RJJ, van der Zant FM. Parathyroid imaging with 18F-fluorocholine PET/CT as a first-line imaging modality in primary hyperparathyroidism: a retrospective cohort study. *EJNMMI Res*. 2019 Dec 1;9(1).
46. Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Gosnell JE, Shen WT, et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. *Langenbeck's Arch Surg*. 2016 Nov 1;401(7):925–35.
47. Yuan L, Liu J, Kan Y, Yang J, Wang X. The diagnostic value of 11C-methionine PET in hyperparathyroidism with negative 99mTc-MIBI SPECT: A meta-analysis. Vol. 58, *Acta Radiologica*. SAGE Publications Inc.; 2017. p. 558–64.
48. Caldarella C, Treglia G, Isgrò MA, Giordano A. Diagnostic performance of positron emission tomography using 11C-methionine in patients with suspected parathyroid adenoma: A meta-analysis. *Endocrine*. 2013 Feb;43(1):78–83.
49. Broos WAM, Van Der Zant FM, Knol RJJ, Wondergem M. Choline PET/CT in parathyroid imaging: a systematic review. Vol. 40, *Nuclear Medicine Communications*. Lippincott Williams and Wilkins; 2019. p. 96–105.
50. Rep S, Hocevar M, Vaupotic J, Zdesar U, Zaletel K, Lezaic L. 18F-choline PET/CT for parathyroid scintigraphy: Significantly lower radiation exposure of patients in comparison to conventional nuclear medicine imaging approaches. *J Radiol Prot*. 2018 Mar 1;38(1):343–56.

PATHOLOGICAL UPTAKE WITH 18-FLUOROCHOLINE VERSUS 99mTc-MIBI IN THE LOCATION OF THE PARATHYROID GLANDS IN HYPERPARATHYROIDISM.
SYSTEMATIC REVIEW AND META-ANALYSIS
PARDAL-REFOYO ET AL.

Figure 1. Bibliographical search and literature selection strategies.

PATHOLOGICAL UPTAKE WITH 18-FLUOROCHOLINE VERSUS 99mTc-MIBI IN THE LOCATION OF THE PARATHYROID GLANDS IN HYPERPARATHYROIDISM.
SYSTEMATIC REVIEW AND META-ANALYSIS
PARDAL-REFOYO ET AL.

Table 1. Subgroup 1: MIBI vs CH as the first scan. Results table.

	CH PET/TC			99mTc-sestamibi SPECT/CT		
study name	N	CAPTURES	NO CAPTURE	N	CAPTURES	NO CAPTURE
Thansser 2017 [17]	54	52	2	54	42	12
Orevi 2014 [21]	40	37	3	40	33	7
Beheshti 2018 [22]	82	76	6	82	50	32
Araz 2018 [24]	35	30	5	35	28	7
Bossert 2019 [25]	34	24	10	34	5	29
Araz 2018 2 [23]	43	42	1	43	35	8
Imamovic 2016 [26]	41	39	2	41	27	14
Hocevar 2017 [27]	151	126	25	90	74	16
Kluijfhout 2016 [28]	44	34	10	44	14	30
Michaud 2015 [14]	17	15	2	17	15	2
Khafif 2019 [19]	19	16	3	19	14	5
Lezaic 2014 [20]	24	24	0	24	20	4
Michaud 2014 [18]	12	11	1	12	7	5
	596	526	70	535	364	171

PATHOLOGICAL UPTAKE WITH 18-FLUOROCHOLINE VERSUS 99mTc-MIBI IN THE LOCATION OF THE PARATHYROID GLANDS IN HYPERPARATHYROIDISM.
SYSTEMATIC REVIEW AND META-ANALYSIS
PARDAL-REFOYO ET AL.

Figure 2. Subgroup 1: MIBI vs CH as the first scan. Forest plot.

Random-Effects Model (k = 13)

	Estimate	se	Z	p	CI Lower Bound	CI Upper Bound
Intercept	1.45	0.293	4.95	< .001	0.875	2.025

Note. Tau² Estimator: Restricted Maximum-Likelihood

[3]

Heterogeneity Statistics

Tau	Tau ²	I ²	H ²	R ²	df	Q	p
0.742	0.5498 (SE= 0.4357)	55.35%	2.239		12.000	29.741	0.003

Back-Transform Log Odds Ratio to Odds Ratio

Odds Ratio	CI Lower Bound	CI Upper Bound
4.264	2.400	7.577

Robust Paired Samples T-Test

		t	df	p	Mean difference	SE	95% Confidence Interval		Cohen's d
							Lower	Upper	
CAPTA_CH	CAPTA_MIBI	3.49	8.00	0.008	7.78	2.23	2.63	12.922	0.317
NOCAPTA_CH	NOCAPTA_MIBI	-2.60	8.00	0.032	-7.67	2.95	-14.48	-0.858	0.731

Figure 3. Statistical heterogeneity.

PATHOLOGICAL UPTAKE WITH 18-FLUOROCHOLINE VERSUS 99mTc-MIBI IN THE LOCATION OF THE PARATHYROID GLANDS IN HYPERPARATHYROIDISM.
SYSTEMATIC REVIEW AND META-ANALYSIS
PARDAL-REFOYO ET AL.

Fail-Safe N Analysis (File Drawer Analysis)

Fail-safe N	p
248.000	< .001

Note. Fail-safe N Calculation Using the Rosenthal Approach

Rank Correlation Test for Funnel Plot Asymmetry

Kendall's Tau	p
-0.103	0.675

Regression Test for Funnel Plot Asymmetry

Z	p
0.678	0.498

Figure 4. Subgroup 1: MIBI vs CH as the first scan. Funnel plot and publication bias

PATHOLOGICAL UPTAKE WITH 18-FLUOROCHOLINE VERSUS 99mTc-MIBI IN THE LOCATION OF THE PARATHYROID GLANDS IN HYPERPARATHYROIDISM.
SYSTEMATIC REVIEW AND META-ANALYSIS
PARDAL-REFOYO ET AL.

Table 2. Subgroup 2: CH as a rescue scan in negative MIBI. Results table.

Study name	N	CAPTURES	NO CAPTURE
Piccardo 2019 [35]	44	32	12
Thansser 2017 [17]	11	11	0
Orevi 2014 [21]	7	7	0
Zajickova 2018 [36]	13	12	1
Kluijfhout 2017 [37]	10	9	1
Quak 2018 [38]	25	22	3
Morales 2018 [39]	49	42	7
Bera 2018 [40]	29	26	3
Amadou 2019 [41]	29	28	1
Liu 2019 [29]	87	70	17
Christakis 2019 [30]	12	12	0
Collaud 2019 [31]	7	6	1
Grimaldi 2018 [32]	27	24	3
Huber 2018 [33]	26	25	1
Kluijfhout 2015 [37]	5	4	1
Treglia 2016 [34]	23	21	2
Araz 2018 2 [23]	8	8	0
	412	359	53

PATHOLOGICAL UPTAKE WITH 18-FLUOROCHOLINE VERSUS 99mTc-MIBI IN THE LOCATION OF THE PARATHYROID GLANDS IN HYPERPARATHYROIDISM.
SYSTEMATIC REVIEW AND META-ANALYSIS
PARDAL-REFOYO ET AL.

Figure 5. Subgroup 2: CH as a rescue scan in negative MIBI. Forest plot.

Random-Effects Model (k = 17)

	Estimate	se	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.902	0.0181	49.7	< .001	0.867	0.938

Note. Tau² Estimator: Restricted Maximum-Likelihood

[3]

Heterogeneity Statistics

Tau	Tau ²	I ²	H ²	R ²	df	Q	p
0.042	0.0018 (SE= 0.0018)	34.5%	1.527	.	16.000	22.101	0.140

Figure 6. Statistical heterogeneity

PATHOLOGICAL UPTAKE WITH 18-FLUOROCHOLINE VERSUS 99mTc-MIBI IN THE LOCATION OF THE PARATHYROID GLANDS IN HYPERPARATHYROIDISM.
SYSTEMATIC REVIEW AND META-ANALYSIS
PARDAL-REFOYO ET AL.

Fail-Safe N Analysis (File Drawer Analysis)

Fail-safe N	p
23348.000	< .001

Note. Fail-safe N Calculation Using the Rosenthal Approach

Rank Correlation Test for Funnel Plot Asymmetry

Kendall's Tau	p
-0.250	0.177

Regression Test for Funnel Plot Asymmetry

Z	p
-0.868	0.386

Figure 7. Subgroup 2: CH as a rescue scan in negative MIBI. Funnel plot and publishing bias.

PATHOLOGICAL UPTAKE WITH 18-FLUOROCHOLINE VERSUS 99mTc-MIBI IN THE LOCATION OF THE PARATHYROID GLANDS IN HYPERPARATHYROIDISM.
SYSTEMATIC REVIEW AND META-ANALYSIS
PARDAL-REFOYO ET AL.

Figure 8. Prevalence of uptake with SPECT/TC-MIBI and PET/TC-Choline in hyperparathyroidism.